Phase III trials that provide the pivotal evidence of efficacy and safety to support the regulatory approval of new drugs represent a major component of the overall cost of drug research and development. Consequently, it is crucial to optimize their operational efficiency. For example, if a phase III trial is estimated to cost US$150 million over three years, then $1 million a week is effectively at risk if a trial is delayed owing to operational issues.

The author declares no competing interests.